Want to see ANTX full AI Analyst Report?
Top Page
AN2 Therapeutics, Inc.
(NASDAQ:ANTX)
Select Model
Select Model
Rating:55Neutral
Price Target:
$6.00
▲(21.95% Upside)
Action:Reiterated
Date:08/19/26
The score is held back primarily by weak financial performance (pre-revenue, ongoing losses, and persistent cash burn despite zero debt). Offsetting factors include constructive technical momentum and a positive corporate catalyst from encouraging Chagas program trial results, while valuation support is limited due to negative earnings and no dividend.
Positive Factors
Zero debt supports financial flexibility
A debt-free balance sheet avoids interest obligations and reduces creditor pressure while programs advance. This gives ANTX greater flexibility to direct capital toward clinical development, although equity financing may still be needed.
Negative Factors
No meaningful commercial revenue
Without approved products or recurring commercial sales, ANTX has no established operating revenue base to absorb research and corporate costs. Financial performance therefore remains highly dependent on clinical progress, partnerships, grants, and future financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero debt supports financial flexibility
A debt-free balance sheet avoids interest obligations and reduces creditor pressure while programs advance. This gives ANTX greater flexibility to direct capital toward clinical development, although equity financing may still be needed.
Read all positive factors
AN2 Therapeutics, Inc. (ANTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$225.29M
Dividend YieldN/A
Average Volume (3M)73.31K
Price to Earnings (P/E)―
Beta (1Y)-0.15
Revenue GrowthN/A
EPS Growth13.97%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.07
Shares Outstanding37,736,237
10 Day Avg. Volume45,687
30 Day Avg. Volume73,314
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-1.15
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside82.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
AN2 Therapeutics, Inc. Business Overview & Revenue Model
Company Description
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole,...
How the Company Makes Money
As a clinical-stage company, AN2 Therapeutics does not have publicly available evidence of recurring product revenue from commercialized/approved therapeutics; accordingly, revenue is primarily expected to be non-commercial in nature. The company’...
AN2 Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -77.00K | 0.00 |
| EBITDA | -37.57M | -35.17M | 3.23M | 4.90M | -40.88M | -21.54M |
| Net Income | -36.28M | -35.17M | -51.32M | -64.73M | -40.96M | -21.54M |
Balance Sheet | ||||||
| Total Assets | 81.68M | 61.95M | 92.09M | 138.74M | 102.56M | 65.32M |
| Cash, Cash Equivalents and Short-Term Investments | 78.39M | 58.00M | 83.62M | 107.30M | 96.06M | 58.55M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 53.00K | 0.00 |
| Total Liabilities | 5.75M | 8.89M | 10.24M | 14.04M | 7.19M | 3.41M |
| Stockholders Equity | 75.92M | 53.06M | 81.85M | 124.70M | 95.37M | 61.91M |
Cash Flow | ||||||
| Free Cash Flow | -30.68M | -29.83M | -49.26M | -53.29M | -33.46M | -20.48M |
| Operating Cash Flow | -30.68M | -29.83M | -49.26M | -53.29M | -33.46M | -20.48M |
| Investing Cash Flow | 17.91M | 28.31M | 54.59M | -43.28M | -21.77M | -50.02M |
| Financing Cash Flow | 38.87M | 113.00K | 372.00K | 84.99M | 70.36M | 78.53M |
AN2 Therapeutics, Inc. Technical Analysis
Positive
4.92
Price Trends
5.09
Positive
4.59
Positive
3.11
Positive
Market Momentum
0.30
Positive
60.61
Neutral
17.47
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANTX, the sentiment is Positive. The current price of 4.92 is below the 20-day moving average (MA) of 5.61, below the 50-day MA of 5.09, and above the 200-day MA of 3.11, indicating a bullish trend. The MACD of 0.30 indicates Positive momentum. The RSI at 60.61 is Neutral, neither overbought nor oversold. The STOCH value of 17.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANTX.
AN2 Therapeutics, Inc. Risk Analysis
AN2 Therapeutics, Inc. disclosed 71 risk factors in its most recent earnings report. AN2 Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AN2 Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $225.29M | -5.57 | -52.35% | ― | ― | 13.97% | |
54 Neutral | $296.63M | -8.66 | -31.41% | ― | ― | 29.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $261.56M | -4.78 | -99.17% | ― | -33.68% | 4.48% | |
45 Neutral | $216.77M | -0.17 | 250.02% | ― | ― | -2012.66% | |
44 Neutral | $308.15M | -1.33 | -242.28% | ― | ― | 21.31% | |
42 Neutral | $203.34M | -1.88 | -57.92% | ― | -19.07% | 2.07% |
* Healthcare Sector Average
ANTX
AN2 Therapeutics, Inc.
5.96
4.84
432.14%
NERV
Minerva Neurosciences
4.79
2.49
108.53%
AVXL
Anavex Life Sciences
3.39
-6.29
-64.98%
VYGR
Voyager Therapeutics
3.41
0.06
1.79%
ACIU
AC Immune SA
2.58
0.44
20.56%
NMRA
Neumora Therapeutics, Inc.
1.64
0.03
1.86%
AN2 Therapeutics, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
AN2 Therapeutics Holds 2026 Annual Stockholder Meeting
Positive
Jun 9, 2026
On June 3, 2026, AN2 Therapeutics, Inc. held its 2026 annual meeting of stockholders, where 63.18% of outstanding shares were represented, constituting a quorum for conducting corporate business. Stockholders elected Kabeer Aziz, Gilbert Lynn Mark...
Business Operations and StrategyProduct-Related Announcements
AN2 Therapeutics Advances Chagas Candidate After Positive Trials
Positive
Jun 4, 2026
On June 4, 2026, AN2 Therapeutics reported positive data from a 28-day nonhuman primate study and a Phase 1 first-in-human trial of its oral CPSF3 inhibitor AN2-502998 for chronic Chagas disease, showing 100% parasite elimination in naturally infe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.